#triple-negative breast cancer

Study Points Immune System at Triple-Negative Breast Cancer

PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.

First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.

Savage X Fenty, the pop superstar’s brand, is known for its dedication to inclusive representation in popular culture.

Adding Tecentriq to a three-drug chemotherapy regimen increases odds of remission of early-stage triple-negative breast cancer.

The honeybee’s sting contains a compound that kills hard-to-treat breast cancer cells quickly.

The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Anne Boyer, a poet and essayist, writes about her experience with triple-negative breast cancer in “The Undying.”

Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.

A study looked at circulating tumor DNA as a biomarker for health outcomes among women with triple-negative breast cancer.